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Alzheimer’s disease (AD) is a devastat-
ing public health problem for our aging 
societies. Although it is well established 
that amyloid β-peptide (Aβ) forms toxic 
oligomers in the brain (Haass and Sel-
koe, 2007), it is not clear how Aβ initiates 
the amyloid cascade and causes the 
death of neurons. Tau, an axonal protein, 
seems to be an executor of Aβ toxicity 
even though it is localized to axons, and 
Aβ toxicity is primarily triggered through 
interactions of Aβ oligomers with den-
dritic spines (Haass and Selkoe, 2007). 
Tau binds to microtubules, a process that 
is prevented by its abnormal phosphory-
lation during AD pathogenesis. Loss of 
microtubule binding by tau is thought to 
cause the disassembly of microtubules 
followed by the aggregation and depo-
sition of tau in pathogenic neurofibril-
lary tangles. Although amyloid plaques 
and tau tangles are prominent markers 
of AD, one of the first and most obvious 
pathological abnormalities observed 
in brain tissue from AD patients is the 
relocalization of tau from axons to the 
somatodendritic compartment of neu-
rons (Figure 1) (Ballatore et al., 2007). 
During brain development, tau and other 
microtubule-associated proteins are ini-
tially distributed ubiquitously throughout 
neurons, but then, as differentiation pro-
gresses, tau becomes sorted into axons 
(Figure 1). In AD and other neurodegen-
erative diseases involving tau (termed 
“tauopathies”), this neat sorting pattern 
breaks down (Ballatore et al., 2007), 
perhaps because abnormal phospho-
rylation of tau enables it to detach from 
microtubules and diffuse rapidly into 
other neuronal compartments (Konzack 
et al., 2007). In this issue of Cell, Ittner 
et al. (2010) now shed light on an unex-
pected dendritic function for normal tau 
that suggests how tau may mediate Aβ 
toxicity.
Most research on tau function has 
focused on whether it is important for 
microtubule stabilization, neurite out-
growth, or the formation of tracks for 
cargo transport along axons. The cata-
strophic redistribution of tau to the soma 
and dendrites of neurons in AD sug-
gests that an efficient sorting mechanism 
normally keeps tau localized to axons. 
However, such “polarized” sorting like 
other cellular sorting pathways is never 
completely efficient, thus enabling small 
amounts of tau to become localized to 
the somatodendritic compartment even 
under physiological conditions. This 
led Ittner and colleagues to propose a 
microtubule-independent physiological 
function for tau that regulates signaling in 
dendritic spines. Their research was ini-
tially triggered by accumulating evidence 
that subacute seizures occur not only in 
transgenic mouse models of AD, but also 
in AD patients (Palop and Mucke, 2009). 
Interestingly, tau deficiency decreases 
seizures induced by the Aβ-mediated 
overstimulation of excitatory N-methyl-D-
aspartate (NMDA) receptors and improves 
survival in a transgenic AD mouse model 
(Roberson et al., 2007).
It is well established that tau binds not 
only to microtubules but also to several 
nonreceptor tyrosine kinases including 
Fyn through its N-terminal domain (Lee 
et al., 1998). This enables tau to seques-
ter Fyn and to alter its localization in the 
neuron. Fyn phosphorylates subunit 2 of 
the NMDA receptor, resulting in stabili-
zation of this receptor’s interaction with 
PSD95, a scaffolding protein in the den-
dritic spines of neurons. This stabiliza-
tion, in turn, strengthens signaling by the 
excitotoxic neurotransmitter glutamate, 
which enhances Aβ toxicity (Figure 1). A 
tau-dependent increase in Fyn in den-
dritic spines could boost excitotoxic sig-
naling, and, conversely, sequestration 
of Fyn by tau or downregulation of tau 
expression could mitigate excitotoxicity.
To address whether this is the case, Itt-
ner and coworkers first generated trans-
genic mice that overexpressed a variant of 
tau (∆tau) that lacked the C terminus and 
thus could bind to Fyn but not to micro-
tubules. Interestingly, ∆tau was completely 
excluded from dendrites and accumulated 
within the soma (Figure 1). Moreover, ∆tau 
efficiently competed with endogenous tau 
for binding to Fyn, resulting in sequestra-
tion of Fyn in the soma. Similarly, loss of 
tau also prevented postsynaptic targeting 
of Fyn, and loss of Fyn in the dendrites 
was enhanced when ∆tau was expressed 
in mice deficient in normal tau. This sug-
gests that the targeting of Fyn to dendrites 
depends on normal tau, a surprising find-
ing for a protein believed to act only in 
axons. But how tau-based sorting of Fyn 
occurs and whether other proteins are 
required remain unclear.
Fyn phosphorylates NMDA receptor 
subunit 2 at tyrosine 1472 and stabilizes 
the interaction of this subunit with the 
postsynaptic protein PSD95 (Nakazawa et 
al., 2001). However, when Fyn is trapped 
within the soma by expression of ∆tau or 
reduced expression of endogenous tau, 
there is decreased phosphorylation of 
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the NMDA receptor, the interaction of the 
receptor with PSD95 is destabilized, and 
excitotoxic signaling decreases. Excito-
toxicity has been implicated in Aß-medi-
ated toxicity, and a reduction in tau ame-
liorates the pathological action of Aβ in 
the AD transgenic mouse model (Rober-
son et al., 2007). Similarly, overexpression 
of ∆tau in the AD mice prevented seizures 
and improved survival; indeed, these ben-
efits were enhanced when expression of 
endogenous tau was reduced. Moreover, 
the AD mice overexpressing ∆tau showed 
improvements in memory, suggesting 
that Aβ toxicity was reduced when Fyn 
levels decreased in the dendritic spines. 
This was independent of Aβ production or 
the overall amyloid plaque load. 
Notably, there is an interesting twist 
to the Fyn-tau-microtubule story. In oli-
godendrocytes, tau is necessary for 
the outgrowth of cell processes and for 
transport of Fyn, which is important for 
myelinating neurons. Expression of the 
N-terminal domain of tau alone causes 
abnormal sorting of Fyn, resulting in poor 
myelination of neurons and seizures in 
rodents (Klein et al., 2002). Thus, there are 
two completely distinct settings for this 
potentially toxic triad, which implicates 
abnormal tau in seizure disorders as well 
as in neurodegenerative diseases.
But can the Fyn-tau connection in den-
dritic spines be exploited to develop new 
therapeutic strategies for treating AD? A 
peptide that blocks phosphorylation of 
NMDA receptors by Fyn protects neu-
rons from excitotoxic damage (Aarts et 
al., 2002). Strikingly, when Ittner and col-
leagues treated their transgenic AD mice 
with this peptide, memory deficits were 
ameliorated and there was improved 
survival, similar to the results when Fyn 
was sequestered by ∆tau.
The Ittner et al. study may provide 
a missing link between extracellular 
deposits of Aβ and intracellular tau and 
pinpoints tau and Fyn as possible medi-
ators of Aβ toxicity. Although the idea is 
tantalizing, the actual colocalization of 
tau and Fyn within dendritic spines and 
their modes of action remain to be shown 
under physiological conditions. A major 
surprise of this study is that a normal 
physiological function of tau, regarded 
as an axonal protein, mediates Aβ tox-
icity at dendritic spines. Is this physio-
logical function of tau affected during the 
earliest stages of AD? This may be the 
case, as redistribution of full-length tau 
(and possibly tau fragments) to the som-
atodendritic compartment occurs well 
before the formation of neurofibrillary 
tangles. The abnormal sorting of tau to 
the somatodendritic compartment may 
be due to changes in signaling cascades 
that alter kinase and phosphatase activi-
ties in those dendritic spines affected by 
Aβ, resulting in local changes in tau sort-
ing and cytoskeletal rearrangements. 
But do tau and Fyn still interact after tau 
redistribution, given that the Fyn bind-
ing site on tau can be phosphorylated 
leading to disruption of this binding? If 
they do, then relocalized tau may boost 
Fyn action in dendrites and hence phos-
phorylation of NMDA receptors, thus 
enhancing excitotoxic signaling and 
increasing the sensitivity of neurons to 
Aβ (Figure 1). However, before targeting 
the tau-Fyn interaction for therapeutic 
purposes, we need to know more about 
the mechanism by which tau medi-
ates the transport of Fyn to dendrites. If 
that transport mechanism is disturbed, 
what other neuronal functions would be 
affected? Clearly, not only Fyn, but also 
other signaling molecules containing 
SH3 domains bind to the PXXP motifs 
in the N-terminal domain of tau and of 
related microtubule-associated proteins; 
but we do not know whether inhibition 
of this binding would have deleterious 
effects. Also, is ∆tau just a scavenger 
that when overexpressed sequesters 
Fyn? Could proteins other than tau per-
form this activity in vivo? The enhanced 
phenotypes upon reduction of endoge-
nous tau seem to speak against this pos-
sibility. The provocative work of Ittner et 
al. raises new challenging questions, but 
also brings us a significant step closer 
to understanding AD pathophysiology. 
Hopefully, these findings will help in the 
design of new therapeutic strategies for 
reducing the synaptic dysfunction and 
neuronal loss of AD and other neurode-
generative diseases.
Figure 1. A Toxic Triad in Alzheimer’s Disease.
Shown is the neuronal localization of tau protein (red) and Fyn kinase (blue) under physiological and 
pathological conditions. 
(Left) Normal tau is primarily located in axons but also interacts with Fyn kinase and targets it to den-
drites. Fyn kinase phosphorylates subunit 2 of the NMDA receptor in dendritic spines, which results 
in stabilization of the receptor’s interaction with the postsynaptic density protein PSD95, leading to 
enhanced excitotoxicity. Excitotoxicity is known to increase the toxic effects of oligomers of Aβ (dark 
purple) on neurons. 
(Middle) Overexpression of a ∆tau variant lacking the C terminus, which binds to Fyn kinase but not to 
microtubules, results in the sequestration of Fyn in the soma, preventing Fyn from reaching the dendrites. 
Consequently, Fyn-mediated phosphorylation of NMDA receptors is decreased and Aβ-mediated toxicity 
is reduced (pale purple). 
(Right) Enhanced redistribution of abnormally hyperphosphorylated tau from axons to the somatoden-
dritic compartment during AD pathogenesis may increase tau-dependent sorting of Fyn to the dendrites, 
boosting excitotoxic signaling and increasing the toxic effects of Aβ (black) on neurons.
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The tumor suppressor protein p53 is 
one of the cell’s most important barri-
ers against oncogenic transformation. By 
regulating the expression of thousands of 
genes, either directly or indirectly, p53 pro-
foundly influences cell fate in response to 
stress. Several decades of research have 
established p53 as a transcriptional acti-
vator with high sequence specificity. How-
ever, p53 clearly also represses at least 
as many genes as it activates, if not more. 
Despite this, the mechanism of repression 
is less well characterized than the trans-
activation mechanism by p53. Now, the 
informative study by Huarte et al. (2010) in 
this issue lays the framework for a new and 
elegant mechanism by which p53 globally 
downregulates a large subset of its repres-
sion targets. These authors show that the 
long intergenic RNA-p21 (lincRNA-p21), a 
bona fide downstream target of p53, is a 
key inhibitor of gene expression through 
its interaction with heterogeneous ribonu-
cleoprotein K (hnRNP-K).
Although the first reports of gene 
repression by p53 focused on suppres-
sion of the basal transcriptional machin-
ery, subsequent studies identified more 
precise mechanisms occurring at specific 
genes (reviewed in Laptenko and Prives, 
2006). These include p53 interacting 
with and inhibiting specific transcription 
factors; displacement of specific activa-
tors from promoters due to the presence 
of overlapping binding sites; the recruit-
ment by p53 of chromatin-modifying 
factors, such as histone deacetylases, 
which then block gene expression; and 
the binding of p53 to unique “repression” 
response elements. In addition, p53 may 
also inhibit genes indirectly by activat-
ing transcription of factors that block 
expression of specific genes. Most nota-
bly, many labs have demonstrated that 
the cell-cycle inhibitor p21 (especially 
within the context of Rb-family activa-
tion) is a critical mediator of p53-depen-
dent transcriptional repression (Figure 
1, top) (Barsotti and Prives, 2009, and 
references therein). Recently, studies 
indicate that p53 regulates microRNAs, 
which either degrade mRNA targets or 
inhibit their translation into protein. The 
p53 protein facilitates not only the tran-
scriptional activation of microRNAs but 
also their processing into mature, active 
forms (Figure 1, middle) (Shi et al., 2010). 
Now, Huarte, Rinn, and their colleagues 
(Huarte et al., 2010) add an exciting new 
route through which p53 executes wide-
spread gene repression, specifically by 
activating a long intergenic RNA (Figure 
1, bottom).
LincRNAs are large RNA molecules 
(primary transcript ≥5 kb) that are evo-
lutionarily conserved across mammalian 
genomes. Although these RNAs are tran-
scribed by RNA polymerase II, 5′capped, 
and polyadenylated like normal mRNAs, 
they do not code for proteins (Guttman 
et al., 2009). Previous work by the Rinn 
group suggested that lincRNAs may 
repress transcription by targeting chro-
matin-modifying complexes to specific 
genomic loci (Khalil et al., 2009).
In their new work, Huarte et al. (2010) 
sought to identify specific lincRNAs that 
operate within the p53 pathway. They con-
structed a tiling microarray designed to 
detect the expression of ?400 lincRNAs. 
They then incubated this array with RNA 
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The tumor suppressor protein p53 coordinates the cellular response to stress through regulation 
of gene expression. Now, Huarte et al. (2010) identify a long intergenic noncoding RNA as a new 
player in p53-mediated repression of genes involved in apoptosis.
